To investigate the effects of novel sodium channel blockers on human and rat SCN2A (NaV1.2) gain-of-function (GOF) variants. Variants were selected to represent diverse locations within the channel protein and diverse GOF mechanisms.
|Effective start/end date||3/28/22 → 9/27/22|
- Neurocrine Biosciences, Inc. (NB AGMT 3-28-22)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.